Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates

Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to pro...

Full description

Bibliographic Details
Main Authors: Neeltje van Doremalen, Robert J. Fischer, Jonathan E. Schulz, Myndi G. Holbrook, Brian J. Smith, Jamie Lovaglio, Benjamin Petsch, Vincent J. Munster
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Viruses
Subjects:
NHP
Online Access:https://www.mdpi.com/1999-4915/13/8/1645